Valuation: Ovid Therapeutics Inc.

Market Cap 527M 459M 435M 395M 738M 50.5B 741M 5.18B 2B 25.66B 1.98B 1.94B 82.16B P/E 2026 *
-7.28x
P/E 2027 * -6.62x
Enterprise Value 527M 459M 435M 395M 738M 50.5B 741M 5.18B 2B 25.66B 1.98B 1.94B 82.16B EV / Sales 2026 *
644x
EV / Sales 2027 * 2,361x
Free-Float
93.28%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Ovid Therapeutics Inc.

1 day+0.75%
1 week+2.66%
Current month+1.12%
1 month-6.57%
3 months+11.57%
6 months+34.33%
Current year+65.64%
1 week 2.63
Extreme 2.63
2.8
1 month 2.61
Extreme 2.61
2.95
Current year 1.36
Extreme 1.36
3.1
1 year 1.16
Extreme 1.16
3.1
3 years 0.24
Extreme 0.2425
4.1
5 years 0.24
Extreme 0.2425
4.14
10 years 0.24
Extreme 0.2425
15.93
Manager TitleAgeSince
Chief Executive Officer 45 2025-12-31
Director of Finance/CFO 59 2026-07-05
Chief Tech/Sci/R&D Officer 60 2025-12-01
Director TitleAgeSince
Chairman 72 2014-03-31
Director/Board Member 81 2015-11-22
Director/Board Member 61 2017-06-13
Date Insider Type Main position Quantity % Market Cap. Importance
7/6/26 Free

Chief Financial Officer

50,000 0.0268%
7/6/26 Other

Chief Financial Officer

450,625 0.2414%
4/7/26 Free

Director

17,578 0.0133%
Change 5-day change 1-year change 3-year change Capi.($)
+0.75%+2.66%+132.76%-31.99% 523M
+1.76%+3.88%+46.85%+101.12% 69.69B
+2.29%+1.43%+38.39%+77.03% 61.24B
+1.14%-2.59%-14.37%+365.92% 26.77B
+2.95%+2.34%+0.52%-12.74% 24.07B
+1.49%+7.73%+26.85%-15.89% 20.39B
-0.83%-9.47%+174.16%+295.44% 15.72B
+3.01%+1.85%+44.63%+168.18% 14.07B
+2.43%+4.24%-2.05%+847.59% 13.8B
+1.00%+0.24%+28.02%+203.83% 12.22B
Average +1.60%+0.86%+47.58%+199.85% 25.85B
Weighted average by Cap. +1.82%+1.73%+36.91%+162.91%

Financials

2026 *2027 *
Net sales 819K 713K 675K 613K 1.15M 78.45M 1.15M 8.04M 3.11M 39.87M 3.08M 3.01M 128M 223K 194K 184K 167K 312K 21.39M 314K 2.19M 848K 10.87M 839K 820K 34.79M
Net income -68.31M -59.5M -56.31M -51.16M -95.58M -6.54B -96.05M -671M -259M -3.32B -257M -251M -10.64B -84.77M -73.84M -69.88M -63.49M -119M -8.12B -119M -832M -322M -4.13B -318M -311M -13.21B
Net Debt - -
Logo Ovid Therapeutics Inc.
Ovid Therapeutics Inc. is a biopharmaceutical company dedicated to developing small-molecule medicines for brain conditions with significant unmet need. It is advancing a pipeline of novel, targeted small-molecule candidates that modulate the intrinsic and extrinsic factors involved in neuronal hyperexcitability causative of multiple neurological and neuropsychiatric disorders. It develops OV329, which is a GABA-aminotransferase inhibitor, as a potential therapy for treatment-resistant seizures and other undisclosed indications; OV350, OV4071 and others within a library of compounds that directly activate the KCC2 transporter, for multiple CNS disorders. It also maintains the KCC2 library, which is a portfolio of potential first-in-class direct activators of potassium chloride cotransporter2. Both OV350 and OV4071 are intended for the potential treatment of psychosis associated with neuronal-synuclein diseases (NSD), which include Parkinson’s disease and Lewy body dementia (LBD).
Employees
23
Date Price Change Volume
26-09-17 $2.700 +0.75% 1,985,827
26-09-16 $2.680 -1.11% 1,428,324
26-09-15 $2.710 -1.09% 988,551
26-09-14 $2.740 +1.86% 1,199,520
26-09-11 $2.690 +2.28% 1,147,532
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
10
Last Close Price
2.700USD
Average target price
5.916USD
Spread / Average Target
+119.09%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. OVID Stock
LAST HOURS | 40% Discount: The Best Subscriber-Only Tools to Unlock Hidden Opportunities!
d
:
:
SEIZE THE OFFER!